Aztreonam inhalation - Gilead Sciences

Drug Profile

Aztreonam inhalation - Gilead Sciences

Alternative Names: AI - Gilead; AZLI; Aztreonam lysine; Cayston; Corus 1020; GS-9268

Latest Information Update: 18 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Gilead Sciences
  • Class Antibacterials; Monobactams; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections
  • Discontinued Bronchiectasis; Burkholderia infections

Most Recent Events

  • 03 Aug 2017 Phase-III clinical trials in Cystic fibrosis-associated respiratory tract infections (In adolescents, In children, In infants) in Spain (Inhalation) (EudraCT2016-002749-42) (NCT03219164)
  • 03 Aug 2017 Phase-III clinical trials in Cystic fibrosis-associated respiratory tract infections (In children, In infants, In adolescents) in USA (Inhalation) (NCT03219164)
  • 13 Jul 2017 Gilead Sciences plans a phase III trial for Cystic-fibrosis-associated respiratory tract infections (In adolescents, In children, In infants) (NCT03219164)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top